Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956545 | 1.00 | KMT2A (0.43) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL5956613 | 0.90 | NFKB1 (0.38) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL5956608 | 0.90 | NFKB1 (0.38) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL5956511 | 0.88 | KMT2A (0.40) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL5956853 | 0.88 | KMT2A (0.40) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL5956821 | 0.88 | KMT2A (0.40) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL5956635 | 0.88 | KMT2A (0.40) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL5956524 | 0.83 | KMT2A (0.55) | KMT2AMEN1TDP1POLBNPC1 | |
| SCHEMBL5956531 | 0.83 | KMT2A (0.55) | KMT2AMEN1TDP1POLBNPC1 | |
| SCHEMBL5956588 | 0.81 | KMT2A (0.36) | KMT2AMEN1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | KMT2A 1253/4885MEN1 2543/4885NFKB1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.